What the FDA labels say about taking them together
Amiodarone and atazanavir
Atazanavir's FDA label of August 6, 2025 names amiodarone in its contraindications section; the amiodarone labels PlainMeds reads (2) do not name atazanavir. The atazanavir label: “Concomitant use of REYATAZ with ritonavir and either quinidine or amiodarone is contraindicated due to the potential for serious or life-threatening reactions such as cardiac arrhythmias. …”
Check it at the source: the amiodarone FDA label on DailyMed (effective December 9, 2025, Chartwell RX, LLC); the atazanavir FDA label on DailyMed (effective August 6, 2025, Aurobindo Pharma Limited).
What does the amiodarone label say about atazanavir?
Amiodarone's label (effective December 9, 2025) and its 1 other brand-application label do not name atazanavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Amiodarone Hydrochloride), Chartwell RX, LLC, effective December 9, 2025 (SPL set 5520f11d-968d-4f4f-bf57-d14369c0d746), via openFDA; the full label on DailyMed
What does the atazanavir label say about amiodarone?
Atazanavir label, contraindicationsDrug Class: Antiarrhythmics; Drugs within class that are contraindicated with atazanavir capsules: Amiodarone (with ritonavir), quinidine (with ritonavir)
Atazanavir label, drug interactionsConcomitant Drug Class/Specific Drugs: Antiarrhythmics: amiodarone, quinidine amiodarone, bepridil, lidocaine (systemic), quinidine; Effect on Concentration of Atazanavir or Concomitant Drug: ↑ amiodarone, bepridil, lidocaine (systemic), quinidine; Clinical Comment: Concomitant use of atazanavir with ritonavir and either quinidine or amiodarone is contraindicated due to the potential for serious or life-threatening reactions such as cardiac arrhythmias [see ]. Coadministration with atazanavir without ritonavir has the potential to produce serious and/or life-threatening adverse events but has not been studied. …
Source: FDA drug label (Reyataz, NDA021567), E.R. Squibb & Sons, L.L.C., effective December 5, 2024 (SPL set 165cff62-b284-4a27-a65d-9ec8a5bfcdd8), via openFDA
Source: FDA drug label (Atazanavir Sulfate), Aurobindo Pharma Limited, effective August 6, 2025 (SPL set 7fbea274-d6b5-4faa-bbf0-05fefab42114), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Amiodarone | Atazanavir | |
|---|---|---|
| Labeled for | n/a | HIV |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.122 per tablet 200 mg tablet | $2.23 per capsule 300 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once